<!DOCTYPE html>
<html>

<head>
    <title>CardioSmart</title>
    <meta charset="utf-8">
    <meta content="width=device-width, initial-scale=1" name="viewport">
    <meta content="yes" name="mobile-web-app-capable">
    <meta content="kss-node" name="generator">
    <link href="https://fonts.googleapis.com/css?family=Lato:400,700,300" rel="stylesheet">
    <link href="kss-assets/vendor/prism.css" rel="stylesheet">
    <link href="kss-assets/css/kss.css" rel="stylesheet">
    <link rel="stylesheet" href="../icons/css/fontawesome.css"/>
<link rel="stylesheet" href="../icons/css/solid.css"/>
<link rel="stylesheet" href="../icons/css/regular.css"/>
<link rel="stylesheet" href="../icons/css/brands.css"/>
<link rel="stylesheet" href="../icons/css/light.css"/>
<link rel="stylesheet" href="../css/styleguide_override.css"/>
<link rel="stylesheet" href="//fonts.googleapis.com/css?family=Roboto+Slab&display=swap"/>
<link rel="stylesheet" href="//fonts.googleapis.com/css?family=Muli&display=swap"/>
<link rel="stylesheet" href="//fonts.googleapis.com/css?family=Maven+Pro&display=swap"/>
<link rel="stylesheet" href="../css/color-code_social.css"/>
<link rel="stylesheet" href="../css/color-code_LOE_COR.css"/>
<link rel="stylesheet" href="../css/color-code_pathway.css"/>
<link rel="stylesheet" href="../css/cardiosmart_boot.css"/>
<link rel="stylesheet" href="../css/cardiosmart_uc.css"/>
<link rel="stylesheet" href="https://pro.fontawesome.com/releases/v5.12.1/css/all.css"/>

</head>

<body class="kss-body">
    <!-- header. -->
    <header class="kss-header">
        <section class="kss-header__inner">
            <a class="kss-header__hamburger-trigger">
                <div class="kss-header__hamburger"></div>
            </a>
            <h1 class="kss-header__title kss-title">CardioSmart</h1>
        </section>
    </header>
    <!-- /header. -->
    <!-- navigation. -->
    <section class="kss-navigation shadow_n2 texture_medium bg_acc overflow_auto scrollbar-mini p-b_5">
        <ul class="arches_site-nav  block bg_black-2 flex flex_column ul_none w_100 shadow_n1 ul_none" id="sitenav">
                <li class="flex_auto ">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/" id="home_nav">Arches</a>
                </li>
                <li class="flex_auto ">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/boot_acc/" id="boot_acc">ACC &amp;  Bootstrap</a>
                </li>
                <li class="flex_auto ">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/boot_journal/" id="boot_journal">JACC &amp; Bootstrap</a>
                </li>
                <li class="flex_auto is-active active">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/boot_cardiosmart/" id="uc_cardiosmart">CardioSmart &amp; Bootstrap</a>
                </li>
                <li class="flex_auto ">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/boot_cvquality/" id="boot_cvquality">CVQualtiy &amp; Bootstrap</a>
                </li>
                <li class="flex_auto ">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/zurb_acc/" id="zurb_acc">ACC &amp; Foundation</a>
                </li>
                <li class="flex_auto ">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/color_codes/" id="color_codes">Color Codes</a>
                </li>
                <li class="flex_auto ">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/layout_demo/" id="layout_demo">Layout Demo</a>
                </li>
                <li class="flex_auto ">
                    <a class="c_white undecorated h:undecorated a:bg_accent h:bg_black-5 p-x_4 p-y_3 block" href="/Arches/boot_virtual/" id="virtual">Virtual Conference</a>
                </li>
        </ul>
        <h1 class="c_white font_2 p-x_4 p-y_3 m-t_3 ">CardioSmart</h1>
        <ul class="bg_black-3 shadow_n1 ul_none">
            <li class="kss-nav__item ">
                <a class="c_white  h:bg_black-2 a:bg_accent h:undecorated" href="index.html">
                    <span class="kss-nav__ref">0</span>
                    <span class="kss-nav__name">Introduction</span>
                </a>
            </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-designbase.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">1</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">Design Base</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-html.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">2</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">Basic HTML</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-interactiveextras.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">3</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">Interactive Extras</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-mixins.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">4</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">mixins</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-sitefinity.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">5</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">Sitefinity</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-uc.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">6</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">Utility Classes</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-recipes.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">7</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">Recipes</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-recipes.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">7</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">CardioSmart Recipes</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-recipespages.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">8</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">CardioSmart: Pages</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-recipesnews.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">9</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">CardioSmart: News Articles</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-recipesrelated.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">10</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">CardioSmart: Related Content</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-recipespatient.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">11</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">CardioSmart: Patient Stories</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-recipesfyhah.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">12</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">FYHAH</span>
                    </a>
                </li>
                <li class="kss-nav__item ">
                    <a class=" c_white h:bg_black-2 a:bg_accent a:c_white flex flex_row flex_nowrap h:undecorated" href="section-recipeschd.html">
                        <span class="kss-nav__ref flex_shrink p-r_4 font_bold w_10">13</span>
                        <span class="kss-nav__name flex_auto  overflow_ellipsis">CHD</span>
                    </a>
                </li>
        </ul>
    </section>
    <!-- /navigation. -->
    <!-- documentation. -->
    <section class="kss-documentation texture_light">
            <!-- display each section, in order. the "root" element comes first in this loop, and can be detected using the "#if @first" block as seen below. -->
                    <header class="bg_white kss-section kss-section--depth-2 shadow_1" id="kssref-html-realarticle">
                <article class="kss-section__content">
                        <p class="kss-section__source">Source: <span>dist/css/cardiosmart_boot_combo.css</span>, line <span>23896</span>
                        </p>
                    <a class="kss-section__permalink" href="#kssref-html-realarticle">
                        <h2 class="kss-section__item kss-section__item--depth-2">
                            <span class="kss-section__ref">2.5</span>
                            <span class="kss-section__name">ACC Article</span>
                        </h2>
                    </a>
                </article>
                    <article class="kss-section__modifiers">
                        <h1 class="kss-modifiers__heading">Example 
                        </h1>
                        <div class="kss-modifiers__example">
                            <div class="max-w_60"><div class="reading-typography">
    <div class="the-text">
        <div class="contribution-to-literature">
            <h2>Contribution To Literature:</h2>
            <p></p>
            <p>The HOME-PE trial showed that risk stratification can identify approximately one-third of PE patients who can be safely treated at home.</p>
            <p></p>
        </div>
        <div class="description">
            <h2>Description:</h2>
            <p></p>
            <p>The goal of the trial was to evaluate two risk stratification tools among patients diagnosed with pulmonary embolism (PE).</p>
            <p></p>
        </div>
        <div class="study-design">
            <h2>Study Design</h2>
            <p></p>
            <ul>
                <li>Randomized</li>
                <li>Parallel</li>
                <li>Open-label</li>
            </ul>
            <p>Eligible patients were randomized to risk stratification with the HESTIA rule (n = 984) versus the simplified Pulmonary Embolism Severity Index (PESI) score (n = 986). Low-risk patients were discharged home, while &gt; low-risk patients were admitted to the hospital.</p>
            <p>The HESTIA rule is considered low-risk if none of the following apply: hemodynamic instability, thrombolysis or embolectomy, active bleeding or high-risk of bleeding, supplemental oxygen, PE diagnosed during anticoagulation treatment, severe pain requiring intravenous medication, medical or social reason for hospitalization, severe renal or hepatic impairment, or pregnancy.</p>
            <p>The PESI score assigns a score for each of the following: age &gt;80 years, history of cancer, chronic cardiopulmonary disease, systolic blood pressure &lt;100 mm Hg, heart rate ≥110 beats per minute, or oxygen saturation &lt;90%. Low risk is considered a score of 0. </p>
            <ul>
                <li>Total number of enrollees: 1,970</li>
                <li>Duration of follow-up: 90 days</li>
                <li>Mean patient age: 64 years</li>
                <li>Percentage female:
                <ul>
                <li>Total number of enrollees: 1,970</li>
                <li>Duration of follow-up: 90 days</li>
                <li>Mean patient age: 64 years</li>
                <li>Percentage female: 48%</li>
            </ul></li>
            </ul>
            <p>Inclusion criteria:</p>
            <ul>
                <li>Patients diagnosed with PE</li>
            </ul>
            <p>Other salient features/characteristics: </p>
            <ul>
                <li>In the HESTIA group, 62% were hospitalized, while 38% were managed at home.</li>
                <li>In the PESI group, 64% were hospitalized, while 36% were managed at home.</li>
            </ul>
            <p></p>
        </div>
        <div class="principal-findings">
            <h2>Principal Findings:</h2>
            <p></p>
            <p>The primary outcome, all-cause death, recurrent VTE, or major bleeding at 30 days, occurred in 3.8% of the HESTIA group compared with 3.6% of the PESI group (p for noninferiority = 0.005). </p>
            <p>Secondary outcomes:</p>
            <ul>
                <li>Proportion of patients actually treated as outpatients: 38.4% of the HESTIA group compared with 36.6% of the PESI group (p for superiority = 0.41)</li>
                <li>Rate of low-risk patients eligible for outpatient care: 39.4% of the HESTIA group compared with 48.4% of the PESI group</li>
                <li>Patients treated as outpatients among eligible patients: 88.4% of the HESTIA group compared with 64.8% of the PESI group</li>
            </ul>
            <p></p>
        </div>
        <div class="interpretation">
            <h2>Interpretation:</h2>
            <p>Among patients with PE, risk stratification with the HESTIA rule was noninferior to the PESI score on all-cause death, recurrent VTE, or major bleeding. The two strategies were similar regarding the proportion of patients treated at home. By using risk stratification, approximately one-third of low-risk patients with PE could be safely managed at home.<br></p>
        </div>
        <div class="legacy-references" id="references-for-article">
            <h2>References:</h2>
            <p></p>
            <p>Presented by Dr. Pierre-Marie Roy at the European Society of Cardiology Virtual Congress, August 31, 2020.</p>
            <p></p>
        </div>
        <p class="topics-list"><b>Clinical Topics:</b> <a href="http://www.acc.org/clinical-topics/anticoagulation-management">Anticoagulation Management, </a><a href="http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention">Invasive Cardiovascular Angiography and Intervention, </a><a href="http://www.acc.org/clinical-topics/prevention">Prevention, </a><a href="http://www.acc.org/clinical-topics/pulmonary-hypertension-and-venous-thromboembolism">Pulmonary Hypertension and Venous Thromboembolism, </a><a href="http://www.acc.org/clinical-topics/vascular-medicine">Vascular Medicine, </a><a href="http://www.acc.org/clinical-topics/anticoagulation-management/anticoagulation-management-and-venothromboembolism">Anticoagulation Management and Venothromboembolism, </a><a href="http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention/interventions-and-vascular-medicine">Interventions and Vascular Medicine</a> </p>
        <p class="keywords-list"><b>Keywords:</b> <i>ESC Congress, </i><i>ESC20, </i><i>Anticoagulants, </i><i>Blood Pressure, </i><i>Embolectomy, </i><i>Hemorrhage, </i><i>Neoplasms, </i><i>Outpatients, </i><i>Patient Discharge, </i><i>Pulmonary Embolism, </i><i>Primary Prevention, </i><i>Risk Assessment, </i><i>Thrombolytic Therapy, </i><i>Thromboembolism, </i><i>Vascular Diseases, </i><i>Venous Thromboembolism</i> </p>
        <a href="#" id="backToListings" class="parent back-to-listing">&lt; Back to Listings</a>
    </div>
</div></div>
                        </div>
                    </article>
                        <section class="relative">
                            <article class="kss-section__markup overflow_scroll scrollbar-mini" style="max-height: 30vh;">
                                <pre><code class="language-markup"  id="input-html-realarticle" value='&lt;div class&#x3D;&quot;reading-typography&quot;&gt;
    &lt;div class&#x3D;&quot;the-text&quot;&gt;
        &lt;div class&#x3D;&quot;contribution-to-literature&quot;&gt;
            &lt;h2&gt;Contribution To Literature:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The HOME-PE trial showed that risk stratification can identify approximately one-third of PE patients who can be safely treated at home.&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;description&quot;&gt;
            &lt;h2&gt;Description:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The goal of the trial was to evaluate two risk stratification tools among patients diagnosed with pulmonary embolism (PE).&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;study-design&quot;&gt;
            &lt;h2&gt;Study Design&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Randomized&lt;/li&gt;
                &lt;li&gt;Parallel&lt;/li&gt;
                &lt;li&gt;Open-label&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Eligible patients were randomized to risk stratification with the HESTIA rule (n &#x3D; 984) versus the simplified Pulmonary Embolism Severity Index (PESI) score (n &#x3D; 986). Low-risk patients were discharged home, while &amp;gt; low-risk patients were admitted to the hospital.&lt;/p&gt;
            &lt;p&gt;The HESTIA rule is considered low-risk if none of the following apply: hemodynamic instability, thrombolysis or embolectomy, active bleeding or high-risk of bleeding, supplemental oxygen, PE diagnosed during anticoagulation treatment, severe pain requiring intravenous medication, medical or social reason for hospitalization, severe renal or hepatic impairment, or pregnancy.&lt;/p&gt;
            &lt;p&gt;The PESI score assigns a score for each of the following: age &amp;gt;80 years, history of cancer, chronic cardiopulmonary disease, systolic blood pressure &amp;lt;100 mm Hg, heart rate ≥110 beats per minute, or oxygen saturation &amp;lt;90%. Low risk is considered a score of 0. &lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Total number of enrollees: 1,970&lt;/li&gt;
                &lt;li&gt;Duration of follow-up: 90 days&lt;/li&gt;
                &lt;li&gt;Mean patient age: 64 years&lt;/li&gt;
                &lt;li&gt;Percentage female:
                &lt;ul&gt;
                &lt;li&gt;Total number of enrollees: 1,970&lt;/li&gt;
                &lt;li&gt;Duration of follow-up: 90 days&lt;/li&gt;
                &lt;li&gt;Mean patient age: 64 years&lt;/li&gt;
                &lt;li&gt;Percentage female: 48%&lt;/li&gt;
            &lt;/ul&gt;&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Inclusion criteria:&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Patients diagnosed with PE&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Other salient features/characteristics: &lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;In the HESTIA group, 62% were hospitalized, while 38% were managed at home.&lt;/li&gt;
                &lt;li&gt;In the PESI group, 64% were hospitalized, while 36% were managed at home.&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;principal-findings&quot;&gt;
            &lt;h2&gt;Principal Findings:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The primary outcome, all-cause death, recurrent VTE, or major bleeding at 30 days, occurred in 3.8% of the HESTIA group compared with 3.6% of the PESI group (p for noninferiority &#x3D; 0.005). &lt;/p&gt;
            &lt;p&gt;Secondary outcomes:&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Proportion of patients actually treated as outpatients: 38.4% of the HESTIA group compared with 36.6% of the PESI group (p for superiority &#x3D; 0.41)&lt;/li&gt;
                &lt;li&gt;Rate of low-risk patients eligible for outpatient care: 39.4% of the HESTIA group compared with 48.4% of the PESI group&lt;/li&gt;
                &lt;li&gt;Patients treated as outpatients among eligible patients: 88.4% of the HESTIA group compared with 64.8% of the PESI group&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;interpretation&quot;&gt;
            &lt;h2&gt;Interpretation:&lt;/h2&gt;
            &lt;p&gt;Among patients with PE, risk stratification with the HESTIA rule was noninferior to the PESI score on all-cause death, recurrent VTE, or major bleeding. The two strategies were similar regarding the proportion of patients treated at home. By using risk stratification, approximately one-third of low-risk patients with PE could be safely managed at home.&lt;br&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;legacy-references&quot; id&#x3D;&quot;references-for-article&quot;&gt;
            &lt;h2&gt;References:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;Presented by Dr. Pierre-Marie Roy at the European Society of Cardiology Virtual Congress, August 31, 2020.&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;p class&#x3D;&quot;topics-list&quot;&gt;&lt;b&gt;Clinical Topics:&lt;/b&gt; &lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/anticoagulation-management&quot;&gt;Anticoagulation Management, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention&quot;&gt;Invasive Cardiovascular Angiography and Intervention, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/prevention&quot;&gt;Prevention, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/pulmonary-hypertension-and-venous-thromboembolism&quot;&gt;Pulmonary Hypertension and Venous Thromboembolism, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/vascular-medicine&quot;&gt;Vascular Medicine, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/anticoagulation-management/anticoagulation-management-and-venothromboembolism&quot;&gt;Anticoagulation Management and Venothromboembolism, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention/interventions-and-vascular-medicine&quot;&gt;Interventions and Vascular Medicine&lt;/a&gt; &lt;/p&gt;
        &lt;p class&#x3D;&quot;keywords-list&quot;&gt;&lt;b&gt;Keywords:&lt;/b&gt; &lt;i&gt;ESC Congress, &lt;/i&gt;&lt;i&gt;ESC20, &lt;/i&gt;&lt;i&gt;Anticoagulants, &lt;/i&gt;&lt;i&gt;Blood Pressure, &lt;/i&gt;&lt;i&gt;Embolectomy, &lt;/i&gt;&lt;i&gt;Hemorrhage, &lt;/i&gt;&lt;i&gt;Neoplasms, &lt;/i&gt;&lt;i&gt;Outpatients, &lt;/i&gt;&lt;i&gt;Patient Discharge, &lt;/i&gt;&lt;i&gt;Pulmonary Embolism, &lt;/i&gt;&lt;i&gt;Primary Prevention, &lt;/i&gt;&lt;i&gt;Risk Assessment, &lt;/i&gt;&lt;i&gt;Thrombolytic Therapy, &lt;/i&gt;&lt;i&gt;Thromboembolism, &lt;/i&gt;&lt;i&gt;Vascular Diseases, &lt;/i&gt;&lt;i&gt;Venous Thromboembolism&lt;/i&gt; &lt;/p&gt;
        &lt;a href&#x3D;&quot;#&quot; id&#x3D;&quot;backToListings&quot; class&#x3D;&quot;parent back-to-listing&quot;&gt;&amp;lt; Back to Listings&lt;/a&gt;
    &lt;/div&gt;
&lt;/div&gt;'>&lt;div class&#x3D;&quot;reading-typography&quot;&gt;
    &lt;div class&#x3D;&quot;the-text&quot;&gt;
        &lt;div class&#x3D;&quot;contribution-to-literature&quot;&gt;
            &lt;h2&gt;Contribution To Literature:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The HOME-PE trial showed that risk stratification can identify approximately one-third of PE patients who can be safely treated at home.&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;description&quot;&gt;
            &lt;h2&gt;Description:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The goal of the trial was to evaluate two risk stratification tools among patients diagnosed with pulmonary embolism (PE).&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;study-design&quot;&gt;
            &lt;h2&gt;Study Design&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Randomized&lt;/li&gt;
                &lt;li&gt;Parallel&lt;/li&gt;
                &lt;li&gt;Open-label&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Eligible patients were randomized to risk stratification with the HESTIA rule (n &#x3D; 984) versus the simplified Pulmonary Embolism Severity Index (PESI) score (n &#x3D; 986). Low-risk patients were discharged home, while &amp;gt; low-risk patients were admitted to the hospital.&lt;/p&gt;
            &lt;p&gt;The HESTIA rule is considered low-risk if none of the following apply: hemodynamic instability, thrombolysis or embolectomy, active bleeding or high-risk of bleeding, supplemental oxygen, PE diagnosed during anticoagulation treatment, severe pain requiring intravenous medication, medical or social reason for hospitalization, severe renal or hepatic impairment, or pregnancy.&lt;/p&gt;
            &lt;p&gt;The PESI score assigns a score for each of the following: age &amp;gt;80 years, history of cancer, chronic cardiopulmonary disease, systolic blood pressure &amp;lt;100 mm Hg, heart rate ≥110 beats per minute, or oxygen saturation &amp;lt;90%. Low risk is considered a score of 0. &lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Total number of enrollees: 1,970&lt;/li&gt;
                &lt;li&gt;Duration of follow-up: 90 days&lt;/li&gt;
                &lt;li&gt;Mean patient age: 64 years&lt;/li&gt;
                &lt;li&gt;Percentage female:
                &lt;ul&gt;
                &lt;li&gt;Total number of enrollees: 1,970&lt;/li&gt;
                &lt;li&gt;Duration of follow-up: 90 days&lt;/li&gt;
                &lt;li&gt;Mean patient age: 64 years&lt;/li&gt;
                &lt;li&gt;Percentage female: 48%&lt;/li&gt;
            &lt;/ul&gt;&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Inclusion criteria:&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Patients diagnosed with PE&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Other salient features/characteristics: &lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;In the HESTIA group, 62% were hospitalized, while 38% were managed at home.&lt;/li&gt;
                &lt;li&gt;In the PESI group, 64% were hospitalized, while 36% were managed at home.&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;principal-findings&quot;&gt;
            &lt;h2&gt;Principal Findings:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The primary outcome, all-cause death, recurrent VTE, or major bleeding at 30 days, occurred in 3.8% of the HESTIA group compared with 3.6% of the PESI group (p for noninferiority &#x3D; 0.005). &lt;/p&gt;
            &lt;p&gt;Secondary outcomes:&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Proportion of patients actually treated as outpatients: 38.4% of the HESTIA group compared with 36.6% of the PESI group (p for superiority &#x3D; 0.41)&lt;/li&gt;
                &lt;li&gt;Rate of low-risk patients eligible for outpatient care: 39.4% of the HESTIA group compared with 48.4% of the PESI group&lt;/li&gt;
                &lt;li&gt;Patients treated as outpatients among eligible patients: 88.4% of the HESTIA group compared with 64.8% of the PESI group&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;interpretation&quot;&gt;
            &lt;h2&gt;Interpretation:&lt;/h2&gt;
            &lt;p&gt;Among patients with PE, risk stratification with the HESTIA rule was noninferior to the PESI score on all-cause death, recurrent VTE, or major bleeding. The two strategies were similar regarding the proportion of patients treated at home. By using risk stratification, approximately one-third of low-risk patients with PE could be safely managed at home.&lt;br&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;legacy-references&quot; id&#x3D;&quot;references-for-article&quot;&gt;
            &lt;h2&gt;References:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;Presented by Dr. Pierre-Marie Roy at the European Society of Cardiology Virtual Congress, August 31, 2020.&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;p class&#x3D;&quot;topics-list&quot;&gt;&lt;b&gt;Clinical Topics:&lt;/b&gt; &lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/anticoagulation-management&quot;&gt;Anticoagulation Management, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention&quot;&gt;Invasive Cardiovascular Angiography and Intervention, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/prevention&quot;&gt;Prevention, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/pulmonary-hypertension-and-venous-thromboembolism&quot;&gt;Pulmonary Hypertension and Venous Thromboembolism, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/vascular-medicine&quot;&gt;Vascular Medicine, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/anticoagulation-management/anticoagulation-management-and-venothromboembolism&quot;&gt;Anticoagulation Management and Venothromboembolism, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention/interventions-and-vascular-medicine&quot;&gt;Interventions and Vascular Medicine&lt;/a&gt; &lt;/p&gt;
        &lt;p class&#x3D;&quot;keywords-list&quot;&gt;&lt;b&gt;Keywords:&lt;/b&gt; &lt;i&gt;ESC Congress, &lt;/i&gt;&lt;i&gt;ESC20, &lt;/i&gt;&lt;i&gt;Anticoagulants, &lt;/i&gt;&lt;i&gt;Blood Pressure, &lt;/i&gt;&lt;i&gt;Embolectomy, &lt;/i&gt;&lt;i&gt;Hemorrhage, &lt;/i&gt;&lt;i&gt;Neoplasms, &lt;/i&gt;&lt;i&gt;Outpatients, &lt;/i&gt;&lt;i&gt;Patient Discharge, &lt;/i&gt;&lt;i&gt;Pulmonary Embolism, &lt;/i&gt;&lt;i&gt;Primary Prevention, &lt;/i&gt;&lt;i&gt;Risk Assessment, &lt;/i&gt;&lt;i&gt;Thrombolytic Therapy, &lt;/i&gt;&lt;i&gt;Thromboembolism, &lt;/i&gt;&lt;i&gt;Vascular Diseases, &lt;/i&gt;&lt;i&gt;Venous Thromboembolism&lt;/i&gt; &lt;/p&gt;
        &lt;a href&#x3D;&quot;#&quot; id&#x3D;&quot;backToListings&quot; class&#x3D;&quot;parent back-to-listing&quot;&gt;&amp;lt; Back to Listings&lt;/a&gt;
    &lt;/div&gt;
&lt;/div&gt;</code></pre>
                            </article>
                            <input class="display_none text-input html-code-input" type="text" name="" id="input-html-realarticle" value='&lt;div class&#x3D;&quot;reading-typography&quot;&gt;
    &lt;div class&#x3D;&quot;the-text&quot;&gt;
        &lt;div class&#x3D;&quot;contribution-to-literature&quot;&gt;
            &lt;h2&gt;Contribution To Literature:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The HOME-PE trial showed that risk stratification can identify approximately one-third of PE patients who can be safely treated at home.&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;description&quot;&gt;
            &lt;h2&gt;Description:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The goal of the trial was to evaluate two risk stratification tools among patients diagnosed with pulmonary embolism (PE).&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;study-design&quot;&gt;
            &lt;h2&gt;Study Design&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Randomized&lt;/li&gt;
                &lt;li&gt;Parallel&lt;/li&gt;
                &lt;li&gt;Open-label&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Eligible patients were randomized to risk stratification with the HESTIA rule (n &#x3D; 984) versus the simplified Pulmonary Embolism Severity Index (PESI) score (n &#x3D; 986). Low-risk patients were discharged home, while &amp;gt; low-risk patients were admitted to the hospital.&lt;/p&gt;
            &lt;p&gt;The HESTIA rule is considered low-risk if none of the following apply: hemodynamic instability, thrombolysis or embolectomy, active bleeding or high-risk of bleeding, supplemental oxygen, PE diagnosed during anticoagulation treatment, severe pain requiring intravenous medication, medical or social reason for hospitalization, severe renal or hepatic impairment, or pregnancy.&lt;/p&gt;
            &lt;p&gt;The PESI score assigns a score for each of the following: age &amp;gt;80 years, history of cancer, chronic cardiopulmonary disease, systolic blood pressure &amp;lt;100 mm Hg, heart rate ≥110 beats per minute, or oxygen saturation &amp;lt;90%. Low risk is considered a score of 0. &lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Total number of enrollees: 1,970&lt;/li&gt;
                &lt;li&gt;Duration of follow-up: 90 days&lt;/li&gt;
                &lt;li&gt;Mean patient age: 64 years&lt;/li&gt;
                &lt;li&gt;Percentage female:
                &lt;ul&gt;
                &lt;li&gt;Total number of enrollees: 1,970&lt;/li&gt;
                &lt;li&gt;Duration of follow-up: 90 days&lt;/li&gt;
                &lt;li&gt;Mean patient age: 64 years&lt;/li&gt;
                &lt;li&gt;Percentage female: 48%&lt;/li&gt;
            &lt;/ul&gt;&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Inclusion criteria:&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Patients diagnosed with PE&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;Other salient features/characteristics: &lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;In the HESTIA group, 62% were hospitalized, while 38% were managed at home.&lt;/li&gt;
                &lt;li&gt;In the PESI group, 64% were hospitalized, while 36% were managed at home.&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;principal-findings&quot;&gt;
            &lt;h2&gt;Principal Findings:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;The primary outcome, all-cause death, recurrent VTE, or major bleeding at 30 days, occurred in 3.8% of the HESTIA group compared with 3.6% of the PESI group (p for noninferiority &#x3D; 0.005). &lt;/p&gt;
            &lt;p&gt;Secondary outcomes:&lt;/p&gt;
            &lt;ul&gt;
                &lt;li&gt;Proportion of patients actually treated as outpatients: 38.4% of the HESTIA group compared with 36.6% of the PESI group (p for superiority &#x3D; 0.41)&lt;/li&gt;
                &lt;li&gt;Rate of low-risk patients eligible for outpatient care: 39.4% of the HESTIA group compared with 48.4% of the PESI group&lt;/li&gt;
                &lt;li&gt;Patients treated as outpatients among eligible patients: 88.4% of the HESTIA group compared with 64.8% of the PESI group&lt;/li&gt;
            &lt;/ul&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;interpretation&quot;&gt;
            &lt;h2&gt;Interpretation:&lt;/h2&gt;
            &lt;p&gt;Among patients with PE, risk stratification with the HESTIA rule was noninferior to the PESI score on all-cause death, recurrent VTE, or major bleeding. The two strategies were similar regarding the proportion of patients treated at home. By using risk stratification, approximately one-third of low-risk patients with PE could be safely managed at home.&lt;br&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;div class&#x3D;&quot;legacy-references&quot; id&#x3D;&quot;references-for-article&quot;&gt;
            &lt;h2&gt;References:&lt;/h2&gt;
            &lt;p&gt;&lt;/p&gt;
            &lt;p&gt;Presented by Dr. Pierre-Marie Roy at the European Society of Cardiology Virtual Congress, August 31, 2020.&lt;/p&gt;
            &lt;p&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;p class&#x3D;&quot;topics-list&quot;&gt;&lt;b&gt;Clinical Topics:&lt;/b&gt; &lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/anticoagulation-management&quot;&gt;Anticoagulation Management, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention&quot;&gt;Invasive Cardiovascular Angiography and Intervention, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/prevention&quot;&gt;Prevention, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/pulmonary-hypertension-and-venous-thromboembolism&quot;&gt;Pulmonary Hypertension and Venous Thromboembolism, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/vascular-medicine&quot;&gt;Vascular Medicine, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/anticoagulation-management/anticoagulation-management-and-venothromboembolism&quot;&gt;Anticoagulation Management and Venothromboembolism, &lt;/a&gt;&lt;a href&#x3D;&quot;http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention/interventions-and-vascular-medicine&quot;&gt;Interventions and Vascular Medicine&lt;/a&gt; &lt;/p&gt;
        &lt;p class&#x3D;&quot;keywords-list&quot;&gt;&lt;b&gt;Keywords:&lt;/b&gt; &lt;i&gt;ESC Congress, &lt;/i&gt;&lt;i&gt;ESC20, &lt;/i&gt;&lt;i&gt;Anticoagulants, &lt;/i&gt;&lt;i&gt;Blood Pressure, &lt;/i&gt;&lt;i&gt;Embolectomy, &lt;/i&gt;&lt;i&gt;Hemorrhage, &lt;/i&gt;&lt;i&gt;Neoplasms, &lt;/i&gt;&lt;i&gt;Outpatients, &lt;/i&gt;&lt;i&gt;Patient Discharge, &lt;/i&gt;&lt;i&gt;Pulmonary Embolism, &lt;/i&gt;&lt;i&gt;Primary Prevention, &lt;/i&gt;&lt;i&gt;Risk Assessment, &lt;/i&gt;&lt;i&gt;Thrombolytic Therapy, &lt;/i&gt;&lt;i&gt;Thromboembolism, &lt;/i&gt;&lt;i&gt;Vascular Diseases, &lt;/i&gt;&lt;i&gt;Venous Thromboembolism&lt;/i&gt; &lt;/p&gt;
        &lt;a href&#x3D;&quot;#&quot; id&#x3D;&quot;backToListings&quot; class&#x3D;&quot;parent back-to-listing&quot;&gt;&amp;lt; Back to Listings&lt;/a&gt;
    &lt;/div&gt;
&lt;/div&gt;'>
                            <a class="absolute bg_shade-3 br_1 br_black-3 br_radius br_solid font_medium h:bg_shade-1 m-r_3 p-x_4 p-y_3 r_3 shadow_overlap-light t_3" onclick="CopyText( '#input-html-realarticle',event )"><i class="far fa-copy"></i> Copy</a>
                        </section>
                    </header>
    </section>
    
    <!-- /documentation. -->
    <!-- scripts. -->
    <script src="kss-assets/vendor/jquery.js"></script>
    <script src="kss-assets/vendor/prism.js"></script>
    <script src="kss-assets/js/kss.js"></script>
    <script>
        function CopyText(id,event) {
            event.preventDefault();
            var $htmlCodeInput =  document.getElementById(id);
            /* Select the text field */
            $htmlCodeInput.select();
            $htmlCodeInput.setSelectionRange(0, 99999); /*For mobile devices*/
            $("body").append($htmlCodeInput);
            /* Copy the text inside the text field */
            document.execCommand("copy");

            /* Alert the copied text */
            alert("Copied the text: " + $htmlCodeInput.value);
        };
    </script>
    <script src="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/js/bootstrap.min.js"></script>
<script src="../js/toggleActive.js"></script>

    <!-- /scripts. -->
</body>

</html>
